-
-
-
-
-
-
-
First Wave BioPharma to Participate In ‘Fireside Chat’ at the 36th Annual Roth Conference
-
-
-
-
-
-
-
First Wave BioPharma (FWBI) CEO Issues Letter to Stockholders, Provides 2024 Outlook
-
-
-
-
-
-
-
First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company
-
-
-
-
-
-
-
First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi
-
-
-
-
-
-
-
First Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation
-
-
-
-
-
-
-
First Wave BioPharma Reaches Enrollment Target for Phase 2 SPAN Adrulipase Clinical Trial in Cystic Fibrosis
-
-
-
-
-
-
-
First Wave BioPharma (FWBI) dosed first patient in Phase 2 trial of adrulipase for EPI in CF
-
922,394 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All